A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact on the Progression of Type 1 diabetes
Latest Information Update: 31 Jan 2024
At a glance
- Drugs GAD65 vaccine (Diamyd) (Primary) ; Vitamin D
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Registrational
- Acronyms DIAGNODE-2
- Sponsors Diamyd Medical AB
- 24 Jan 2024 Results describing significant protective effect of endogenous insulin production on several hypoglycemic measures, (episodes of below normal blood glucose levels), published in the Diamyd Medical AB Media Release.
- 06 Jun 2022 Results published in the Media Release
- 06 Jun 2022 Results assessing the efficacy of intralymphatic GAD-alum on blood glucose recorded by continuous glucose monitoring published in the Journal of Clinical Endocrinology and Metabolism